{"id":7101,"date":"2024-02-21T08:00:00","date_gmt":"2024-02-21T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/"},"modified":"2024-02-21T08:00:00","modified_gmt":"2024-02-21T07:00:00","slug":"nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/","title":{"rendered":"Nanexa publicerar bokslutskommunik\u00e9 och Q4-rapport 2023"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Klinisk pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 inl\u00e4mnad, finansiering s\u00e4krad och taktiska prioriteringar f\u00f6r 2024<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>V\u00e4sentliga h\u00e4ndelser under fj\u00e4rde kvartalet 2023<\/strong><\/p>\n<ul>\n<li>Nanexa meddelade att fas I-studien NEX-20-01 har slutf\u00f6rts. Ut\u00f6ver tidigare kommunicerad positiva resultat fr\u00e5n den farmakokinetiska utv\u00e4rderingen erh\u00f6ll bolaget slutliga s\u00e4kerhets- och tolerabilitetsdata som ocks\u00e5 st\u00f6djer projektets vidare utveckling.<\/li>\n<li>Nanexa offentliggjorde utfallet i bolagets f\u00f6retr\u00e4desemission om cirka 121 MSEK, som visade att 42 146 268 aktier, motsvarande cirka 34,7 procent av f\u00f6retr\u00e4desemissionen, hade tecknats med och utan st\u00f6d av teckningsr\u00e4tter. D\u00e4rmed utnyttjades garanti\u00e5taganden om 32 853 732 aktier, motsvarande cirka 27,1 procent av erbjudna aktier och f\u00f6retr\u00e4desemissionen tillf\u00f6rde bolaget 75 MSEK f\u00f6re avdrag f\u00f6r transaktionskostnader.<\/li>\n<li>Nanexa tecknade ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med ett av de st\u00f6rsta globala l\u00e4kemedelsbolagen, f\u00f6r utv\u00e4rdering av Nanexas drug delivery-system, PharmaShell\u00ae, i en dep\u00e5formulering av en monoklonal anitikropp.<\/li>\n<li>Nanexa meddelade att den kliniska pr\u00f6vningsans\u00f6kan f\u00f6r fas I-studien av NEX-22 i patienter med typ 2-diabetes har emottagits och validerats av den europeiska l\u00e4kemedelsmyndigheten EMA.<\/li>\n<li>Nanexas styrelse beslutade att fokusera verksamheten till tre nyckelomr\u00e5den. Beslutet inneb\u00e4r taktiska prioriteringar och kostnadsbesparingar med m\u00e5ls\u00e4ttning att dagens kassa och f\u00f6rv\u00e4ntade int\u00e4kter fr\u00e5n utv\u00e4rderingsavtal ska r\u00e4cka till halv\u00e5rsskiftet 2025 och m\u00f6jligg\u00f6ra betydande v\u00e4rdeskapande framsteg i prioriterade samarbeten och det egna projektet NEX-22.<\/li>\n<\/ul>\n<p><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/p>\n<ul>\n<li>Inga v\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng.<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 oktober \u2013 31 december 2023<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 6 816 (819) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -51 367 (-17 869) kSEK<\/li>\n<li>Periodens resultat uppgick till: -51 150 (-17 932) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,52 (-0,35) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: 44 599 (35 574) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 65 168 (81 182) kSEK<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 januari \u2013 31 december 2023<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 29 327 (2 860) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -76 625 (-57 981) kSEK<\/li>\n<li>Periodens resultat uppgick till: -76 398 (-58 571) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -1,09 (-1,16) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -16 014 (-24 478) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 65 168 (81 182) kSEK<\/li>\n<li>Styrelsen f\u00f6resl\u00e5r att ingen utdelning l\u00e4mnas f\u00f6r r\u00e4kenskaps\u00e5ret 2023.<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida: <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" rel=\"noopener\" target=\"_blank\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p><strong>Rapportkommentar 21 februari kl 11:30<\/strong><br \/>En lives\u00e4nd kommentar med vd David Westberg och CFO Bj\u00f6rn Svanstr\u00f6m h\u00e5lls den 21 februari kl 11:30 via Infront Direkt Studios och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p>Rapportkommentaren kommer att finnas tillg\u00e4nglig via <a href=\"https:\/\/youtube.com\/live\/5lLyPVUo80Y\" rel=\"noopener\" target=\"_blank\">denna l\u00e4nk<\/a>.<br \/>Rapportkommentaren kommer \u00e4ven att l\u00e4ggas upp p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2024-02-21 08:00 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/a89f4cff-3e52-4f05-a1ac-090768ad9857\/nanexa-bokslutskommunike-2023.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa Bokslutskommunike 2023<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Klinisk pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 inl\u00e4mnad, finansiering s\u00e4krad och taktiska prioriteringar f\u00f6r 2024<\/p>\n","protected":false},"template":"","class_list":["post-7101","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim-q4_sv","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar bokslutskommunik\u00e9 och Q4-rapport 2023 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar bokslutskommunik\u00e9 och Q4-rapport 2023 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Klinisk pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 inl\u00e4mnad, finansiering s\u00e4krad och taktiska prioriteringar f\u00f6r 2024\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\\\/\",\"name\":\"Nanexa publicerar bokslutskommunik\u00e9 och Q4-rapport 2023 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-02-21T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar bokslutskommunik\u00e9 och Q4-rapport 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar bokslutskommunik\u00e9 och Q4-rapport 2023 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar bokslutskommunik\u00e9 och Q4-rapport 2023 - Nanexa AB","og_description":"Klinisk pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 inl\u00e4mnad, finansiering s\u00e4krad och taktiska prioriteringar f\u00f6r 2024","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/","name":"Nanexa publicerar bokslutskommunik\u00e9 och Q4-rapport 2023 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-02-21T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-och-q4-rapport-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar bokslutskommunik\u00e9 och Q4-rapport 2023"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}